Ovid Therapeutics Inc

Ovid Therapeutics Inc

OVID

Get informed when a big investor buys or sells

+ Follow
Market Cap$522.59M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ovid Therapeutics IncOvid Therapeutics Inc-7.9--16%-0.1
$7.00

Target Price by Analysts

146.5% upsideOvid Therapeutics Target Price DetailsTarget Price
$-1.87

Current Fair Value

165.8% downside

Overvalued by 165.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$522.59 Million
Enterprise Value$523.98 Million
Dividend Yield$- (-)
Earnings per Share$-0.24
Beta0.23
Outstanding Shares197,453,293

Return

Return on Equity-16.43%ROE
Return on Assets-14.87%
Return on Invested Capital-26.45%

Valuation & Multiples

P/E Ratio-7.87P/E Ratio
PEG-3.57PEG
Price to Sales-Price to Sales
Price to Book Ratio2.84Price to Book Ratio
Enterprise Value to Revenue331
Enterprise Value to EBIT-8.92
Enterprise Value to Net Income-16
Total Debt to Enterprise0.02
Debt to Equity0.06Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 18, 2026
EPS Estimate
$-0.12
Average shareholder expectation
Revenue Estimate
$64,286
Average shareholder expectation

Next Earnings Call

Expected Date
November 11, 2026
EPS Estimate
$-0.12
Average shareholder expectation
Revenue Estimate
$17,750
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.6257▲ 137.34%
Total Calls110,600▼ 10.01%
Total Puts179,800▲ 480.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %142.49%▲ 58.58%
Total Invested$233.18M▲ 131.58%
Investors Holding109▲ 19.00%

ESG Score

No data

About Ovid Therapeutics Inc

CEO: Jeremy Levin